Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1

• NASDAQ: $OTLK
• Notified: $1.44
• 08:05 EDT